Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,963 matching trials from the live ClinicalTrials.gov search.

Filters: Sponsor: Eli Lilly and Company Clear all

Conditions: Type 2 Diabetes
Interventions: Exenatide, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 45 Years to 70 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Spondylitis, Ankylosing
Interventions: Ixekizumab, Placebo, Adalimumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 34
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Upland, California + 31 more

Conditions: Leukemia
Interventions: LY2510924, Idarubicin, Cytarabine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetes Complications, Fatty Liver
Interventions: exenatide; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 70 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Healthy Volunteers
Interventions: Evacetrapib, Digoxin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Advanced Dedifferentiated Liposarcoma
Interventions: Abemaciclib, Placebo; Drug
Lead sponsor: Sarcoma Alliance for Research through Collaboration; Other
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 9
States / cities: Aurora, Colorado • Jacksonville, Florida • Chicago, Illinois + 6 more

Conditions: Sjögren's Syndrome
Interventions: LY3090106, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 4
States / cities: Baltimore, Maryland • Albuquerque, New Mexico • Concord, North Carolina + 1 more

Conditions: Type 2 Diabetes
Interventions: Dulaglutide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 38
States / cities: Glendale, California • Greenbrae, California • Huntington Park, California + 35 more

Conditions: Endometrial Cancer
Interventions: Abemaciclib, Letrozole; Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 29
States / cities: Mobile, Alabama • Anchorage, Alaska • Greenwich, Connecticut + 24 more

Conditions: Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer
Interventions: LY4052031, Pembrolizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 22
States / cities: Duarte, California • La Jolla, California • Los Angeles, California + 15 more

Conditions: Adult Hepatocellular Carcinoma, Metastatic Malignant Neoplasm in the Liver
Interventions: Image-Guided Adaptive Radiation Therapy, Stereotactic Body Radiation Therapy; Radiation
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Lymphoma
Interventions: bortezomib, gemcitabine hydrochloride; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 3
States / cities: Chicago, Illinois

Conditions: Alzheimer's Disease
Interventions: LY2811376, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 20 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Glendale, California

Conditions: Diabetes Mellitus, Type 2
Interventions: Not listed
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 189,426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Overweight
Interventions: LY3437943, Ethinyl Estradiol, Drospirenone; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 40 Years to 60 Years · Female only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: South Miami, Florida • San Antonio, Texas

Conditions: Small Cell Lung Cancer
Interventions: Prexasertib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 14
States / cities: Fayetteville, Arkansas • New Haven, Connecticut • Washington D.C., District of Columbia + 9 more

Conditions: Obesity
Interventions: Retatrutide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 33
States / cities: Santa Ana, California • Aurora, Colorado • Hamden, Connecticut + 30 more

Conditions: Overweight, Healthy
Interventions: LY3541105, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 206 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Lenexa, Kansas • San Antonio, Texas

Conditions: Bladder Cancer
Interventions: Gemcitabine,, Cisplatin, Cetuximab; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 14
States / cities: Duarte, California • Los Angeles, California • Stanford, California + 11 more

Conditions: Gallbladder Cancer, Biliary Tract Cancer
Interventions: Gemcitabine, Cisplatin; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus, Type 2
Interventions: Pioglitazone 15 mg, Pioglitazone 45 mg, Pioglitazone 30 mg, Linagliptin 5mg / Pioglitazone 45 mg FDC, Linagliptin 5mg / Pioglitazone 30 mg FDC, Linagliptin 5mg, Linagliptin 5mg / Pioglitazone 15 mg FDC; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 936 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 74
States / cities: Birmingham, Alabama • Montgomery, Alabama • Muscle Shoals, Alabama + 60 more

Conditions: Alzheimer Disease, Healthy
Interventions: LY3372993, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 139 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 10
States / cities: Cypress, California • Long Beach, California • DeLand, Florida + 6 more

Conditions: Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Cancer
Interventions: LY3499446, Abemaciclib, Cetuximab, Erlotinib, Docetaxel; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: Indianapolis, Indiana • Middletown, New Jersey • Harrison, New York + 1 more

Conditions: Multiple Sclerosis
Interventions: Duloxetine Hydrochloride (HCI), Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 16
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 13 more

Search by objective public record fields.

Impact of Exenatide on Cardiovascular Exercise Performance in Type 2 Diabetes

Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS)

LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease

A Study of Evacetrapib and Digoxin in Healthy Participants

SARC041: Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma

A Study of LY3090106 in Participants With Sjögren's Syndrome (SS)

A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy

Abemaciclib and Letrozole to Treat Endometrial Cancer

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

MRI-Guided Stereotactic Body Radiation Therapy in Treating Patients With Liver Metastases or Liver Cancer

A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma

A Safety Study of LY2811376 Single Doses in Healthy Subjects

Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin

A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese

A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer

A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity

A Study of LY3541105 in Healthy and Overweight Participants

Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer

Gemcitabine and Cisplatin for Gallbladder and Biliary Tract Cancer

30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks

A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy Participants

A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation

Duloxetine for Multiple Sclerosis Pain